Study the Effect of Topical Application of 1% Stachys lavandulifolia Extract Gel vs Diclofenac Gel in Knee Osteoarthritis on the pain and functional disability in patients with primary monoarticular knee osteoarthritis

Study the effect of topical application of 1% Stachys lavandulifolia extract gel and Declofenac gel in knee osteoarthritis on the pain and functional disability in patients with primary monoarticular knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190125042486N1

Enrollment

150

Registered

2019-02-22

Start date

2018-03-21

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary monoarticular knee osteoarthritis. Osteoarthritis, unspecified site

Interventions

Intervention 1: Intervention group: Topical Gel Aqueous Hydrochloric Acid Extract with 200 mg of Celecoxib Capsule. Intervention 2: Control group: Topical Gel Placebo with 200 mg Celcioxide Capsules.

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: A definite diagnosis of primary osteoarthritis in a knee based on the doctor's diagnostic criteria the existence of pain at least for two weeks before beginning treatment the age range between 45 years to 75 years old

Exclusion criteria

Exclusion criteria: Primary osteoarthritis in both patient's knees Acute disease in liver or kidney Ulcer pepticemia Diabetes Thyroid or parathyroid disease Rheumatic arthritis coagulation disease or consumption of anticoagulant drugs History of ischemic stroke or hemorrhage History of deep vein thrombosis History of intra-articular injection during the last 6 weeks Sensitivity to each form of anti-inflammatory drugs Acute and pregnancy trauma History of alcohol use and drug abuse Skin diseases, infection or ulcers in the location of tropical use of medication Oral use of other anti-inflammatory drugs and other effective compounds in the treatment of osteoarthritis 10 days before the beginning of the study History of fracture or knee surgery

Design outcomes

Primary

Measure	Time frame
Pain and functional disability. Timepoint: Six weeks. Method of measurement: Data were collected by interview, Western Ontario and McMaster Universities Arthritis Index Standard Questionnaire (WOMAC), and Vase Analog scale(VAS).	—

Secondary

Measure	Time frame
Patient's function status. Timepoint: 4 times and days 0, 14,28, 42. Method of measurement: intensity of pain by Visual Analog Scale (VAS) scale and the rate of pain on the patient,s function by Western Ontario and McMaster Universities Arthritis Index(WOMAC) questionnaire were measured.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHsmidreza Asadian

Shahre-kord University of Medical Sciences

m_asadian67@yahoo.com+98 38 3333 0061

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026